Evidence map›Paper›PMID 25122922›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2014

The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling.

Youcai Deng, Jianhong Chu, Yulin Ren, Zhijin Fan, Xiaotian Ji, Bethany Mundy-Bosse, Shunzong Yuan, Tiffany Hughes, Jianying Zhang, Baljash Cheema and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. The immunostimulatory activity ofFrontiers in pharmacology · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Youcai DengDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210; Institute of Materia Medica, College of Pharmacy, Third Military Medical University, Chongqing 400038, China;
Jianhong ChuThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
Yulin RenDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210;
Zhijin FanThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; State Key Laboratory of Elemento-Organic Chemistry, Nankai University, Tianjin 300071, China;
Xiaotian JiState Key Laboratory of Elemento-Organic Chemistry, Nankai University, Tianjin 300071, China;
Bethany Mundy-BosseThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
Shunzong YuanThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; Department of Lymphoma, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China;
Tiffany HughesThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
Jianying ZhangCenter for Biostatistics, The Ohio State University, Columbus, OH 43210;
Baljash CheemaDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210;
Andrew T CamardoThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210;
Yong XiaDepartment of Molecular and Cellular Biochemistry, The Ohio State University College of Medicine, Columbus, OH 43210;
Lai-Chu WuDepartment of Molecular and Cellular Biochemistry, The Ohio State University College of Medicine, Columbus, OH 43210;
Li-Shu WangDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226; and.
Xiaoming HeDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210.
A Douglas KinghornDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210;
Xiaohui LiInstitute of Materia Medica, College of Pharmacy, Third Military Medical University, Chongqing 400038, China; jianhua.yu@osumc.edu michael.caligiuri@osumc.edu lpsh008@aliyun.com.
Michael A CaligiuriDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210; The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; jianhua.yu@osumc.edu michael.caligiuri@osumc.edu lpsh008@aliyun.com.
Jianhua YuDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210; The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210; jianhua.yu@osumc.edu michael.caligiuri@osumc.edu lpsh008@aliyun.com.
The Ohio State University · USArmy Medical University · CNAcademy of Military Medical Sciences · CNMedical College of Wisconsin · USNankai University · CN

Funding

Project 3:Isolation Chemistry of Filamentous Fungi and Biological EvaluationP01CA125066 · NCI · OHIO STATE UNIVERSITY · PI JIMMY ORJALA · 2007 to 2026
$27.2M
The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI KEITH LLOYD LIGON · 2013 to 2026
$26.0M
ONOCOLOGY TRAINING GRANTT32CA009338 · NCI · OHIO STATE UNIVERSITY · PI BYRD, JOHN C., POLLOCK, RAPHAEL E. · 1985 to 2018
$8.3M
IL-15--CHARACTERIZATION THROUGH EXPERIMENTAL IMMUNOLOGYR01CA068458 · NCI · ROSWELL PARK CANCER INSTITUTE · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 1996 to 2019
$4.5M
Tumor ImmunologyT32CA090223 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E. · 2002 to 2023
$4.1M
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer PreventionR01CA185301 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 2015 to 2019
$1.8M
IL-15 characterization through experimental immunologyR37CA068458 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2010 to 2014
$1.4M
Elucidate and Modulate TGF-b Signaling in NK Cells for Glioma TreatmentR01CA155521 · NCI · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2012 to 2014
$921k
CDX-301 and Plerixafor Combination in Stem Cell Mobilization for TransplantationR41OD018403 · OD · CELLDEX THERAPEUTICS, INC. · PI MARSH, HENRY, YU, JIANHUA · 2013 to 2013
$111k
NCI NIH HHS CA068458NCI NIH HHS CA125066NCI NIH HHS CA155521NCI NIH HHS CA163205NCI NIH HHS P01 CA125066NCI NIH HHS P01 CA163205NCI NIH HHS R01 CA068458NCI NIH HHS R01 CA155521NCI NIH HHS R01 CA185301NCI NIH HHS R37 CA068458NCI NIH HHS T32 CA009338NCI NIH HHS T32 CA090223NIH HHS OD018403NIH HHS R41 OD018403
6 · The paper itself

Abstract

Natural products are a major source for cancer drug development. NK cells are a critical component of innate immunity with the capacity to destroy cancer cells, cancer-initiating cells, and clear viral infections. However, few reports describe a natural product that stimulates NK cell IFN-γ production and unravel a mechanism of action. In this study, through screening, we found that a natural product, phyllanthusmin C (PL-C), alone enhanced IFN-γ production by human NK cells. PL-C also synergized with IL-12, even at the low cytokine concentration of 0.1 ng/ml, and stimulated IFN-γ production in both human CD56(bright) and CD56(dim) NK cell subsets. Mechanistically, TLR1 and/or TLR6 mediated PL-C's activation of the NF-κB p65 subunit that in turn bound to the proximal promoter of IFNG and subsequently resulted in increased IFN-γ production in NK cells. However, IL-12 and IL-15Rs and their related STAT signaling pathways were not responsible for the enhanced IFN-γ secretion by PL-C. PL-C induced little or no T cell IFN-γ production or NK cell cytotoxicity. Collectively, we identify a natural product with the capacity to selectively enhance human NK cell IFN-γ production. Given the role of IFN-γ in immune surveillance, additional studies to understand the role of this natural product in prevention of cancer or infection in select populations are warranted.

Indexed as

BenzodioxolesCD56 AntigenCells, CulturedGlycosidesHEK293 CellsHumansInterferon-gammaInterleukin-12Interleukin-15Killer Cells, NaturalLymphocyte ActivationReceptors, Interleukin-15RNA InterferenceRNA, Small InterferingSignal TransductionToll-Like Receptor 1BenzodioxolesCD56 AntigenGlycosidesIL15 protein, humanInterferon-gammaInterleukin-12Interleukin-15NCAM1 protein, humanphyllanthusmin CReceptors, Interleukin-15RNA, Small InterferingTLR6 protein, humanToll-Like Receptor 1Toll-Like Receptor 6Transcription Factor RelA

Identifiers

PMID25122922
PMCPMC4162489
OpenAlexW1889778016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.